Based on the data presented in this study, a clinical study to evaluate whether drug repurposing of belimumab for BAFF neutralization can serve to improve response to small molecule inhibitor treatment in CLL is in preparation. Here, TNFSF13B is linked to B-cell chronic lymphocytic leukemia.